EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON HEMOGLOBIN LEVELS AMONG PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROL TRIAL

Authors

  • Jingjo Saisa-ard Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine
  • Ouppatham Supasyndh Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine
  • Bancha Satirapoj Division of Nephrology, Department of Medicine, Phramongkutklao Hospital and College of Medicine

DOI:

https://doi.org/10.55374/jseamed.v2i2.16

Keywords:

Anemia, ACE inhibitors, Chronic kidney disease

Abstract

Background: Anemia commonly occurs among patients with advanced stage chronic kidney disease (CKD) and has been associated with poor clinical outcomes. The role of angiotensin converting enzyme (ACE) inhibitors in aggravating the anemia of patients with CKD is controversial. Objective: To evaluate the effect of ACE inhibitors on hemoglobin levels among patients with advanced CKD. Method: Twenty-two patients with CKD stages IV or V and presenting stable hemoglobin levels over 12 weeks were randomly assigned either to receive enalapril (N=10) or amlodipine (N=12) among those whose blood pressure was controlled with antihypertensives other than ACE inhibitors. Hemoglobin level was monitored at 8 and 16 weeks after treatment. Results: Clinical characteristics were similar at baseline between the enalapril and amlodipine-treated groups, and no difference was observed in blood pressure control during follow-up. Enalapril exhibited no significant change in hemoglobin levels from 11.1 (IQR 11.1 to 11.5) g/dL at baseline to 11.4 (IQR 10 to 12) g/dL at 8 weeks and 10.7 (IQR 9.9 to 11.8) g/dL at 16 weeks of treatment. Hemoglobin levels during the 16-week follow-up declined on average by -0.3 (IQR -0.9 to 0.4) g/dL per 16 weeks in the enalapril group and by -0.1 (IQR-0.7 to 0.4) per 16 weeks in the amlodipine group (P=0.868). Conclusion: Administration of ACE inhibitors on blood pressure control was not associated with declining hemoglobin levels among patients with advanced CKD. Additional studies are necessary to confirm this result.

Metrics

Metrics Loading ...

References

Mikhail A, Brown C, Williams JA, et al. Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease. BMC Nephrol 2017;18:345. DOI: https://doi.org/10.1186/s12882-017-0688-1

Li Y, Shi H, Wang WM, et al. Prevalence, awareness, and treatment of anemia in Chinese patients with nondialysis chronic kidney disease: First multicenter, cross-sectional study. Medicine (Baltimore) 2016;95:e3872. DOI: https://doi.org/10.1097/MD.0000000000003872

Sato Y, Yanagita M. Renal anemia: from incurable to curable. Am J Physiol Renal Physiol 2013;305:F1239-48. DOI: https://doi.org/10.1152/ajprenal.00233.2013

Griffing GT, Melby JC. Enalapril (MK-421) and the white cell count and haematocrit. Lancet 1982;1:1361. DOI: https://doi.org/10.1016/S0140-6736(82)92430-8

Fyhrquist F, Karppinen K, Honkanen T, Saijonmaa O, Rosenlof K. High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J Intern Med 1989;226:257-60. DOI: https://doi.org/10.1111/j.1365-2796.1989.tb01390.x

Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE. Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991;17:199-205. DOI: https://doi.org/10.1016/S0272-6386(12)81129-2

Sica DS. Pharmacotherapy in congestive heart failure: ACE inhibitors and anemia in congestive heart failure. Congest Heart Fail 2000;6:330-2. DOI: https://doi.org/10.1111/j.1527-5299.2000.80177.x

Julian BA, Brantley RR, Jr., Barker CV, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998;9:1104-8. DOI: https://doi.org/10.1681/ASN.V961104

Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. Nephrol Dial Transplant 1995;10:2107-9.

Onoyama K, Sanai T, Motomura K, Fujishima M. Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients. J Cardiovasc Pharmacol 1989;13 Suppl 3:S27-30. DOI: https://doi.org/10.1097/00005344-198900133-00007

Hirakata H, Onoyama K, Iseki K, Kumagai H, Fujimi S, Omae T. Worsening of anemia induced by long-term use of captopril in hemodialysis patients. Am J Nephrol 1984;4:355-60. DOI: https://doi.org/10.1159/000166851

Hirakata H, Onoyama K, Hori K, Fujishima M. Participation of the renin-angiotensin system in the captopril-induced worsening of anemia in chronic hemodialysis patients. Clin Nephrol 1986;26:27-32.

Reid CD, Fidler J, Oliver DO, Cotes PM, Pippard MJ, Winearls CG. Erythroid progenitor cell kinetics in chronic haemodialysis patients responding to treatment with recombinant human erythropoietin. Br J Haematol 1988;70:375-80. DOI: https://doi.org/10.1111/j.1365-2141.1988.tb02497.x

Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis 2001;38:510-7. DOI: https://doi.org/10.1053/ajkd.2001.26839

Nomura S, Sasaki T, Kitano Y, Osawa G. Effects of ACE inhibitor on renal anemia in predialysis patients. Nephron 1996;73:336-7. DOI: https://doi.org/10.1159/000189073

Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008;73:630-6. DOI: https://doi.org/10.1038/sj.ki.5002746

Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int 2001;60:1910-6. DOI: https://doi.org/10.1046/j.1523-1755.2001.00028.x

Abu-Alfa AK, Cruz D, Perazella MA, Mahnensmith RL, Simon D, Bia MJ. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients. Am J Kidney Dis 2000;35:1076-82. DOI: https://doi.org/10.1016/S0272-6386(00)70043-6

Cheungpasitporn W, Thongprayoon C, Chiasakul T, Korpaisarn S, Erickson SB. Renin-angiotensin system inhibitors linked to anemia: a systematic review and meta-analysis. QJM 2015;108:879-84. DOI: https://doi.org/10.1093/qjmed/hcv049

Beckingham IJ, Woodrow G, Hinwood M, et al. A randomized placebo-controlled study of enalapril in the treatment of erythrocytosis after renal transplantation. Nephrol Dial Transplant 1995;10:2316-20. DOI: https://doi.org/10.1093/ndt/10.12.2316

Naito M, Kawashima A, Akiba T, Takanashi M, Nihei H. Effects of an angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitors on burst forming units-erythroid in chronic hemodialysis patients. Am J Nephrol 2003;23:287-93. DOI: https://doi.org/10.1159/000072705

Rousseau-Plasse A, Wdzieczak-Bakala J, Lenfant M, et al. Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo. Exp Hematol 1998;26:1074-9.

Lenfant M, Wdzieczak-Bakala J, Guittet E, Prome JC, Sotty D, Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc Natl Acad Sci U S A 1989;86:779-82 DOI: https://doi.org/10.1073/pnas.86.3.779

Downloads

Published

2018-12-26

How to Cite

1.
Saisa-ard J, Supasyndh O, Satirapoj B. EFFECT OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ON HEMOGLOBIN LEVELS AMONG PATIENTS WITH ADVANCED CHRONIC KIDNEY DISEASE: A RANDOMIZED CONTROL TRIAL. J Southeast Asian Med Res [Internet]. 2018 Dec. 26 [cited 2024 Apr. 17];2(2):103-9. Available from: https://jseamed.org/index.php/jseamed/article/view/16

Issue

Section

Original Articles

Most read articles by the same author(s)

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.